Weiss Ratings Reaffirms “Sell (D-)” Rating for Firefly Neuroscience (NASDAQ:AIFF)

Firefly Neuroscience (NASDAQ:AIFF)‘s stock had its “sell (d-)” rating reissued by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Firefly Neuroscience Stock Performance

Firefly Neuroscience stock opened at $2.94 on Wednesday. The firm has a market cap of $39.54 million, a PE ratio of -1.18 and a beta of 2.11. The firm’s 50 day moving average price is $2.79 and its two-hundred day moving average price is $3.04. Firefly Neuroscience has a twelve month low of $1.86 and a twelve month high of $17.20.

Firefly Neuroscience (NASDAQ:AIFF) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter. Firefly Neuroscience had a negative return on equity of 464.02% and a negative net margin of 5,335.75%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AIFF. Citadel Advisors LLC acquired a new position in shares of Firefly Neuroscience during the 4th quarter worth $30,000. FNY Investment Advisers LLC acquired a new position in shares of Firefly Neuroscience during the 1st quarter worth $89,000. Finally, Geode Capital Management LLC increased its stake in shares of Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after purchasing an additional 58,067 shares during the last quarter. Institutional investors and hedge funds own 4.96% of the company’s stock.

Firefly Neuroscience Company Profile

Firefly Neuroscience, Inc, a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder.